Molecular testing in non-small cell lung cancer: A consensus recommendation.

Autor:	Lai GGY; Division of Medical Oncology, National Cancer Centre Singapore., Cheng XM; Division of Pathology, Singapore General Hospital, Singapore., Ang YL; Department of Haematology-Oncology, National University Cancer Institute, NUH Medical Centre, Singapore., Chua KLM; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore., Samol J; Department of Medical Oncology, Tan Tock Seng Hospital, Singapore., Soo R; Department of Haematology-Oncology, National University Cancer Institute, NUH Medical Centre, Singapore., Tan DSW; Division of Medical Oncology, National Cancer Centre Singapore., Lim TKH; Division of Pathology, Singapore General Hospital, Singapore., Lim DWT; Division of Medical Oncology, National Cancer Centre Singapore.
Jazyk:	angličtina
Zdroj:	Annals of the Academy of Medicine, Singapore [Ann Acad Med Singap] 2023 Jul 28; Vol. 52 (7), pp. 364-373. Date of Electronic Publication: 2023 Jul 28.
DOI:	10.47102/annals-acadmedsg.2022473
Abstrakt:	Introduction: Lung cancer remains an important cause of cancer-related mortality in Singapore, with a greater proportion of non-smokers diagnosed with non-small cell lung cancer (NSCLC) in the past 2 decades. The higher prevalence of targetable genomic alterations in lung cancer diagnosed in Singapore compared with countries in the West, as well as the expanding therapeutic landscape for NSCLC in the era of precision medicine, are both factors that underscore the importance of efficient and effective molecular profiling. Method: This article provides consensus recommendations for biomarker testing for early-stage to advanced NSCLC. These recommendations are made from a multidisciplinary group of lung cancer experts in Singapore with the aim of improving patient care and long-term outcomes. Results: The recommendations address the considerations in both the advanced and early-stage settings, and take into account challenges in the implementation of biomarker testing as well as the limitations of available data. Biomarker testing for both tumour tissue and liquid biopsy are discussed. Conclusion: This consensus statement discusses the approaches and challenges of integrating molecular testing into clinical practice for patients with early- to late-stage NSCLC, and provides practical recommendations for biomarker testing for NSCLC patients in Singapore.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu